Last reviewed · How we verify
gamma-Linolenic acid
Gamma-linolenic acid (GLA), a polyunsaturated omega-6 fatty acid, is under investigation for various conditions including atopic dermatitis, multiple sclerosis, and menopause symptoms. Despite no FDA approval, GLA shows promise in early-phase clinical trials and has a relatively safe profile.
At a glance
| Generic name | gamma-Linolenic acid |
|---|---|
| Sponsor | FDA Office of Orphan Products Development |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gamma-Linolenic acid CI brief — competitive landscape report
- gamma-Linolenic acid updates RSS · CI watch RSS
- FDA Office of Orphan Products Development portfolio CI